Erlotinib in combined therapy of common lung adenocarcinoma in the presence of EGFR gene mutation

S. V. Orlov, A. M. Lozhkina, S. V. Odintsova, M. A. Sviridenko, A. O. Cheremnykh, M. A. Urtenova, E. A. Filippova
2019 Medical Council  
The article presents data on the efficacy of erlotinib in the treatment of NSCLC in the presence of EGFR gene mutation. Its advantages over chemotherapy in terms of survival, quality of life, and tolerability of treatment, both as monotherapy and in combination with cytostatics and other targeted drug – VEGF inhibitor – Bevacizumab, are shown. A clinical case of EGFR-positive NSCLC and its treatment with erlotinib was considered. Ways of overcoming resistance to treatment are studied. The use
more » ... studied. The use of erlotinib should be considered as one of the standard methods of first and subsequent therapy in patients with NSCLC in later stages with confirmed mutations of the EGFR gene.
doi:10.21518/2079-701x-2019-10-64-71 fatcat:s2a2ttcef5hp5pdhdpfygb6d44